CAMBRIDGE, Mass., April 2, 2026
AvenCell Therapeutics, Inc. has achieved a major regulatory milestone with both the U.S. FDA granting Investigational New Drug (IND) clearance and the European Medicines Agency (EMA) approving the Clinical Trial Application (CTA) for its QUADvance Phase I/II study, evaluating AVC-203, a next-generation CRISPR-engineered allogeneic CAR-T therapy targeting relapsed/refractory B-cell malignancies. This dual regulatory approval across major global markets highlights the growing momentum in off-the-shelf cell therapies, positioning AVC-203 as a promising candidate in the evolving landscape of precision immuno-oncology.
Dual-Target CAR-T Innovation Targets B-Cell Malignancies
AVC-203 represents a cutting-edge allogeneic CAR-T platform designed to simultaneously target CD19 and CD20 antigens, which are widely expressed across B-cell malignancies including non-Hodgkin lymphoma, multiple myeloma, and B-cell acute lymphoblastic leukemia (B-ALL). By incorporating dual antigen targeting, the therapy aims to improve tumor cell eradication while reducing the risk of antigen escape, a key limitation in earlier CAR-T approaches.
The investigational therapy also integrates CRISPR/Cas9 gene editing technology, enabling immune evasion mechanisms that prevent graft-versus-host disease (GvHD) and rejection by the patient’s immune system, thereby enhancing safety and persistence. Additionally, the therapy features a switchable targeting system, allowing flexibility to expand treatment to additional tumor antigens in the future, making it a highly adaptable and scalable immunotherapy platform.
Phase I/II QUADvance Study to Evaluate Safety and Efficacy
Advertisement
The QUADvance (AVC-203-01) clinical trial is a multi-center Phase I/II study set to be conducted across the United States and Europe, evaluating key parameters including safety, tolerability, pharmacokinetics, and anti-tumor efficacy in adult patients with relapsed or refractory B-cell cancers. The trial design includes an initial dose-escalation Phase Ia, followed by dose-expansion Phase Ib, and ultimately a Phase II pivotal study, enabling a comprehensive assessment of clinical benefit.
This structured approach aims to generate robust data supporting the therapy’s clinical performance and regulatory advancement. Given the significant burden of B-cell malignancies, with approximately 120,000 and 150,000 new cases annually in the United States and Europe respectively, the successful development of AVC-203 could address a substantial unmet medical need in hematologic oncology.
Off-the-Shelf CAR-T Strategy Enhances Scalability and Access
Unlike traditional autologous CAR-T therapies, which require patient-specific cell manufacturing, AVC-203 leverages an allogeneic “off-the-shelf” approach using donor-derived T cells, enabling immediate treatment availability, improved manufacturing consistency, and significantly reduced production costs. This innovation has the potential to overcome critical limitations in current CAR-T therapies, including complex logistics, long manufacturing timelines, and high costs, which often restrict patient access.
By enabling mass-scale production and rapid deployment, AvenCell aims to make cell therapy more accessible and widely available, particularly for patients with aggressive and rapidly progressing cancers. The company’s broader vision focuses on creating universal, switchable CAR-T platforms capable of targeting multiple cancer types, further expanding the therapeutic potential of this technology.
With global regulatory approvals secured and clinical trials underway, AVC-203 stands at the forefront of next-generation CAR-T innovation, combining gene editing, dual targeting, and scalable manufacturing to redefine treatment possibilities in hematologic malignancies and accelerate the transition toward more accessible, effective cancer immunotherapies.
Source: AvenCell press release
